Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hospital Infanta Sofia | OTHER |
| Universidad Politecnica de Madrid | OTHER |
| IMDEA Food | OTHER |
| Instituto de Investigación en Ciencias de la Alimentación (CIAL) |
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this pilot study was to evaluate the feasibility and acceptability of the ALIBIRD platform, a new mobile health (mHealth) application prototype design for personalized and remote support on the follow-up of cancer patients. The ALIBIRD platform is a mHealth intervention that tracks PROs, improving symptom control and allowing real-time feedback, and provides personalized recommendations and educational content, promoting empowerment and encourage healthy lifestyle behaviors in patients with thoracic neoplasms in active treatment.
The investigators have developed an innovative mHealth platform that provides personalized recommendations based on Patient Reported Outcomes (PROs) records and the study of patient´s nutrigenomics and gut microbiome. The usability of the ALIBIRD mHealth platform prototype is being tested in a 28-week pilot study carried out at Infanta Sofía Hospital. A small group of stage IV thoracic neoplasms patients (n=20) were asked to participate. All the participants gave informed consent.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ALIBIRD mHealth platform | Experimental | Participants are followed-up using the ALIBIRD mHealth platform. The ALIBIRD platform is made up of a mobile application for patients and a web application for the healthcare team. Through the ALIBIRD mobile application, patients regularly register Patients Reported Outcomes (PROs) and Patients Reported Outcome Measures (PROMs) regarding lifestyle (diet, physical activity, sleep, mood), and get access to individualized recommendations in order to assume more responsibility for achieving the best outcomes from their care. Moreover, the patient application includes features for tracking the appearance of symptoms, with alerts sent to the healthcare team in response to these parameters. In addition, the application contains articles and educational information. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ALIBIRD mHealth platform | Device | Use of a mHealth platform to follow-up and empower cancer patients in the self-management of their own health. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Usability and feasibility assesment | Changes in Satisfaction System Usability Scale (SUS) | week 1 to 28 |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Mediterranean Diet Serving Score (MDSS) | Mediterranean adherence assesment | Week 1 to 28 |
| Changes in Quality of life ( European Quality of Life-5 Dimensions 5 Levels questionnaire,EQ-5D-5L) from baseline |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| María Sereno Moyano, Medicine | Fundación Investigación E Innovación Biomédica Hospital Universitario Infanta Sofia-Henares | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Servicio de Oncología. Hospital Infanta Sofía | San Sebastián de los Reyes | Madrid | 28134 | Spain |
Not provided
| ID | Term |
|---|---|
| D013899 | Thoracic Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
Quality of life assesment. The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
In the VAS the individual scores his or her health between two extremes, 0 and 100, the worst and best state of health imaginable.
| Week 1 to 28 |
| Changes in physical activity (International Physical Activity Questionnaire,PAQ) | Physical activity assesment | Week 1 to 28 |
| Changes in sleep (Pittsburg questionnaire) | Sleep assesment | Week 1 to 28 |
| Changes in Quality of life ( The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13, EORTC QLQ-LC-13) | Quality of life assesment. The LC13 covers 13 typical symptoms of lung cancer patients, such as coughing, pain, dyspnea, sore mouth, peripheral neuropathy, and hair loss. questions along 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning) and nine symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) All items are scored from 1 to 4 in relation to the presence of the symptom: not at all, a little, quite a bit, very much. | Week 1 to 28 |
| Changes in toxicity (Patient-Reported Outcome version of the Common Terminology Criteria for Adverse Events, PRO-CTAE questionnaire) | Toxicity assesment | week 1 to 28 |
| Changes is Hospital Anxiety and Depression Questionnaire (HADs) from baseline | Emotional status assesment. This is a scale containing two subscales with 7 anxiety symptoms (HADS-A) and 7 depression symptoms (HADS-D). The items are scored on a 4-point Likert frequency scale (0-3) with a total score ranging from 0 to 21 for each subscale, where a higher score is indicative of greater symptom severity. | Week 1 to 28 |
| Changes in Massachusetts General Hospital-Sexual Functioning Questionnaire (MGH-SFQ) from baseline | Sexuality assesment | Week 1 to 28 |
| Changes is medication adherence (MMAS-8 questionnaire) | Medication adherence assesment | Week 1 to 28 |
| Changes in belief in medication (Beliefs about Medicines Questionnaire,BMQ) | Belief in medication assesment | Week 1 to 28 |